Their results suggested that the concomitant blockade of both CD39 and CD73 immunosuppressive enzymes can limit adenosine-mediated T cell inhibition, thereby enhancing anti-tumor immunity (126). This evidence concerns the gene ENTPD1 and neoplasm.